Avitinib maleate (Abivertinib) is a third-generation, irreversible, and orally active selective EGFR inhibitor. It has IC50 values of 0.18 nM against EGFR L858R and EGFR T790M, and 7.68 nM against wild-type EGFR. Additionally, Avitinib maleate acts as a BTK inhibitor, inducing apoptosis and inhibiting BTK phosphorylation in mantle cell lymphoma. This compound demonstrates anticancer effects and is intended for research use only.
- Third-generation, irreversible, and orally active selective EGFR inhibitor.
- Potent inhibition of mutant EGFR phosphorylation with high selectivity over wild-type EGFR.
- Inhibits phosphorylation of downstream targets such as Akt and ERK1/2 in specific cell lines.
- Also functions as a BTK inhibitor, inducing apoptosis and inhibiting BTK phosphorylation in mantle cell lymphoma.
- Demonstrates anticancer effects in xenograft models, inhibiting EGFR-mutant tumor growth.